Hunan Qiyuan Law Firm (hereinafter referred to as "this firm") has been entrusted by Hunan Shengjing Shanhe Biotechnology Co., Ltd. (hereinafter referred to as "the company" or "the issuer") to act as special legal counsel for the issuer's initial public offering and listing (hereinafter referred to as "this issuance"). This firm has conducted legal verification and validation regarding matters related to this issuance.
This firm has issued the "Legal Opinion on the Initial Public Offering and Listing of Hunan Shengjing Shanhe Biotechnology Co., Ltd." (hereinafter referred to as "the Legal Opinion") and the "Lawyer's Work Report on the Initial Public Offering and Listing of Hunan Shengjing Shanhe Biotechnology Co., Ltd." (hereinafter referred to as "the Lawyer's Work Report") in accordance with the Company Law of the People's Republic of China (hereinafter referred to as "the Company Law"), the Securities Law of the People's Republic of China (hereinafter referred to as "the Securities Law"), and other relevant laws and regulations, as well as the "Administrative Measures for the Initial Public Offering and Listing" issued by the China Securities Regulatory Commission (hereinafter referred to as "CSRC"), and the "Rules for the Disclosure of Information by Companies Issuing Securities No. 12 - Legal Opinions and Lawyer's Work Reports" (hereinafter referred to as "Rule No. 12").
In response to the requirements of CSRC's feedback notice No. 100643 (hereinafter referred to as "the feedback"), this firm has conducted a verification of matters related to this issuance and issued the "Supplementary Legal Opinion (I) on the Initial Public Offering and Listing of Hunan Shengjing Shanhe Biotechnology Co., Ltd." (hereinafter referred to as "the Supplementary Legal Opinion (I)").
This firm expresses legal opinions based on facts that occurred or existed prior to the issuance date of the Supplementary Legal Opinion (I) and in accordance with current laws, regulations, and relevant provisions of the CSRC. The issuance of the Supplementary Legal Opinion (I) is based on the issuer's assurance that it has provided this firm with all necessary, truthful original written materials, copies, or oral testimonies for the issuance of legal opinions.
This firm has strictly fulfilled its statutory responsibilities, adhered to the principles of diligence and good faith, and conducted thorough verification of the issuer's actions and the legality, compliance, authenticity, and validity of this application, ensuring that the Supplementary Legal Opinion (I) contains no false records, misleading statements, or significant omissions.
The Supplementary Legal Opinion (I) is intended solely for the issuer's use in this issuance and shall not be used for any other purpose. The Supplementary Legal Opinion (I) is a supplementary document to the Legal Opinion and should be used in conjunction with the Legal Opinion. In case of any inconsistencies between the Legal Opinion and the Supplementary Legal Opinion (I), the Supplementary Legal Opinion (I) shall prevail.
This firm agrees to submit the Supplementary Legal Opinion (I) as a necessary statutory document for the issuer's issuance, along with other application materials, and shall bear corresponding legal responsibilities for the issued supplementary legal opinion.
This firm agrees that the issuer may partially or wholly cite the content of the Supplementary Legal Opinion (I) in the "Prospectus for the Initial Public Offering and Listing of Hunan Shengjing Shanhe Biotechnology Co., Ltd. (Draft)" as required by the CSRC, but the issuer shall ensure that such citations do not lead to legal ambiguities or misinterpretations, and shall submit the relevant documents involving citations to this firm for review and confirmation before submission or issuance.
Unless otherwise specified in the Supplementary Legal Opinion (I), the definitions in the Lawyer's Work Report shall apply to this supplementary legal opinion.